Breaking News Instant updates and real-time market news.

IPXL

Impax

$18.10

1.35 (8.06%)

08:39
07/18/17
07/18
08:39
07/18/17
08:39

Technical View: Impax trades higher, analyst action

Shares were last up over 2.4% to $18.55. At that price next resistance is at $19.94. Support is at $18.09. Piper Jaffray upgraded the stock to Neutral and raised its price target from $9 to $16.

  • 09

    Aug

IPXL Impax
$18.10

1.35 (8.06%)

07/18/17
PIPR
07/18/17
UPGRADE
Target $16
PIPR
Neutral
Impax upgraded to Neutral from Underweight at Piper Jaffray
Piper Jaffray analyst David Amsellem upgraded Impax Laboratories to Neutral and raised his price target for the shares to $16 from $9. The company is now better positioned to return to earnings growth following the approval of an AB-rated generic form of Concerta, Amsellem tells investors in a research note. He sees "ample room" for Impax to gain a "significant foothold" in the Concerta market.
06/16/17
CANT
06/16/17
INITIATION
Target $20
CANT
Overweight
Impax initiated with an Overweight at Cantor
Cantor Fitzgerald analyst Louise Chen started Impax Laboratories with an Overweight rating and $20 price target.
06/09/17
JANY
06/09/17
NO CHANGE
Target $25
JANY
Buy
Janney see meaningful upside potential for Collegium after FDA removes Opana
After the FDA requested that Endo (ENDP) remove reformulated Opana ER from the market, Janney Capital analyst Ken Trbovich said that the nearly 500,000 Opana prescriptions filled in the last 12-months will switch to products such as Collegium's (COLL) Xtampza and Impax Laboratories' (IPXL) generic oxymoprhone ER. The news brings "meaningful potential upside" for Collegium, which has already shown through comparative studies that Xtampza has superior abuse-deterrent features, stated Trbovich, who reiterates his Buy rating and $25 fair value estimate on Collegium shares.
06/09/17
DBAB
06/09/17
NO CHANGE
Target $20
DBAB
Buy
Impax could benefit from FDA action on Opana, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert believes Impax (IPXL), as the company marketing the only generic of the old Opana ER, could benefit from the FDA's surprise request that Endo (ENDP) remove its reformulated Opana ER from the market. The analyst does not expect the FDA to take action against other oxymorphone products, including Impax's. Gilbert has a Buy rating on Impax with a $20 price target.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.